[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629317":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":25,"centralContacts":29,"locations":37,"responsibleParty":55,"collaborators":20,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":64,"sex":65,"minAge":66,"maxAge":20,"enrollmentInfo":67,"targetDuration":20,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":39,"whyStopped":20,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Washington University School of Medicine","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"dosimetry and AAA patients","Patients who have abdominal aortic aneurysm and healthy volunteers",[12,13],"Drug: Cu-64-RYM2","Drug: PET imaging using Cu-64",[15,21],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Cu-64-RYM2","PET\u002FCT scan",[9],null,{"type":16,"name":22,"description":23,"armGroupLabels":24,"otherNames":20},"PET imaging using Cu-64","PET\u002FCT at different timepoints",[9],[26],{"name":27,"affiliation":5,"role":28},"Robert Gropler, MD","PRINCIPAL_INVESTIGATOR",[30,35],{"name":31,"role":32,"phone":33,"phoneExt":20,"email":34},"Kitty Harrison, RN, BSN","CONTACT","314-747-0183","kittydharrison@wustl.edu",{"name":27,"role":32,"phone":33,"phoneExt":20,"email":36},"rgropler@wustl.edu",[38],{"facility":5,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"RECRUITING","St Louis","Missouri","63110","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-90.19789,38.62727,{"lat":49,"lon":48},[52,53,54],{"name":31,"role":32,"phone":33,"phoneExt":20,"email":34},{"name":27,"role":32,"phone":33,"phoneExt":20,"email":20},{"name":27,"role":28,"phone":20,"phoneExt":20,"email":20},{"type":56,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100629317","early-phase-1-pet-imaging-of-mmp-activation-in-aaa-clinical-component-100629317",false,"NCT07473102","PET Imaging of MMP Activation in AAA: Clinical Component","PET AAA","Inclusion Criteria: Healthy Volunteers\n\n* No history of claustrophobia or other preventing condition that has previously or would interfere with completion of protocol-specified imaging sessions.\n* Able to comprehend and willing to follow instructions for the study procedures as called for by the protocol.\n* Capable of lying still and supine within the PET\u002FCT scanner for \\~1 hour and follow instructions for breathing protocol during the CT portion.\n* No illicit drug use or other inhaled drug use (including pharmacologic agents, recreational agents, or illicit drugs) within the past year.\n* No known history of cardiac, pulmonary, hepatic or renal disease or diabetes\n* BMI ≤ 40\n\nExclusion Criteria: Healthy Volunteers\n\n* Inability to receive and sign informed consent;\n* Pregnant (confirmed by urine pregnancy test) and\u002For breastfeeding\n* Patient with chronic renal disease whose glomerular filtration rate (GFR) is less than 30 mL\u002Fmin\u002F1.73 m2\n* Patients with an unstable clinical condition that in the opinion of the principal investigators or designee precludes participation in the study.\n* Is deemed likely to be unable to perform all research procedures for any reason, (e.g., subjects unable to lie still or inability to tolerate up to 60 minutes in a supine position with arms up during the PET imaging procedures due to chronic back\u002Fshoulder pain or arthritis as assessed by physical examination and medical history).\n* Currently using recreational drugs.\n* Body weight of \\>300 lbs. (weight limit of the PET table).\n* Currently enrolled in another study using an investigational drug or underwent a study the last year involving investigational use of radiotracers or CT would confound results or with a radiation exposure when combined with this study would be deemed as excessive by the Sponsor-Investigator.\n\nInclusion Criteria: Patients with AAA electively or semi-electively scheduled for surgical repair\n\n* Men or women 40-80 years of age\n* Willing and able to provide informed consent\n* Medically managed hypertension and hyperlipidemia\n* No history of claustrophobia or other preventing condition that has previously or would interfere with completion of protocol-specified imaging sessions\n* Able to comprehend and willing to follow instructions for the study procedures as called for by the protocol\n* Patients with AAA indicated for surgical repair (5.0 \\[female\\] - 5.5cm \\[male\\]), incidentally identified large(r) AAAs (\\>5.5 or 6.0 cm), and rapidly expanding AAAs (\\> 0.5 cm in 6 months or \\> 1 cm in 12 months) per Guidelines of the Society for Vascular Surgery.\n\nExclusion Criteria: Patients with AAA electively or semi-electively scheduled for surgical repair\n\n* Inability to receive and sign informed consent.\n* Currently enrolled in another study using an investigational drug\n* Pregnant (confirmed by urine pregnancy test) and\u002For breastfeeding\n* Patient with chronic renal disease whose GFR is less than 30 mL\u002Fmin\u002F1.73 m2\n* Documented allergy to iodinated contrast and\u002For shellfish\n* Patients with an unstable clinical condition that in the opinion of the principal investigators or designee precludes participation in the study.\n* Inability to tolerate 60 minutes in a supine position with arms down at sides, as necessary for PET\u002FCT.\n* Other conditions such as symptomatic\u002Frecently treated coronary disease, cancer requiring oncologic management, or autoimmune\u002Finflammatory diseases (e.g., rheumatoid arthritis or multiple sclerosis).\n* Non-AAA volunteers may not carry a diagnosis of aortoiliac occlusive disease, as documented by their treating vascular surgeon, as significantly progressed atherosclerotic disease may demonstrate exaggerated, associated MMP activity.",true,"ALL","18 Years",{"count":68,"type":69},28,"ESTIMATED","INTERVENTIONAL",[72],"EARLY_PHASE1","A first-in-human evaluation of \\[64Cu\\]-RYM2 with PET\u002FCT will be performed to: a) assess its safety, biodistribution, and radiation dosimetry in normal volunteers (WU) and; b) in AAA patients undergoing surgery (WU and Yale), evaluate radiotracer pharmacodynamics and correlate PET imaging characteristics (WU) with ex vivo tissue measurements (Yale).",[75],"Abdominal Aortic Aneurysm",[77,78],"Imaging for Aneurysm Abdominal","Imaging for Abdominal Aneurysms","2026-03-16",{"date":81,"type":82},"2026-03-18","ACTUAL",{"date":84,"type":82},"2025-11-03",{"date":86,"type":69},"2027-03-31",{"name":5,"class":6},1]